Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. Across healthcare, AI-enabled diagnostic solutions are flooding the market. From cardiology and imaging to oncology and primary care, clinicians are being asked to evaluate algorithms that promise earlier detection, better accuracy, and more efficient care. Many of these tools are technically impressive. Some are FDA-cleared. A few even come with early clinical data. Yet only a relatively small number have become part of routine clinical practice.
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Related Articles
Anumana’s ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status
Medical Product Outsourcing: Artificial intelligence (AI)-driven healthtech company, Anumana has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its AI-enhanced, ECG-based pulmonary hypertension (PH) early detection algorithm.…May 23, 2022
Mayo Clinic finds algorithm helped clinicians detect heart disease, as part of broader AI diagnostics push
Med City News: Mayo Clinic shared results of a study showing that an AI tool developed by the system could be used to improve diagnosis of low ejection fraction, a…May 08, 2021
FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new…June 21, 2023
StartUp Health Insights: Virta & 1Doc3 Close Rounds, Over $1.4B Raised This Week
Health Transformer: Anumana, a startup designing neural network algorithms to enable early detection and accelerate treatment of heart disease, raised $25.7M led by founders nference and Mayo Clinic, with participation…April 20, 2021